medline.ch Onkologie Urologische Tumoren

	Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non-Deficient or Unknown Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO-2 Trial. Int J Urol Yajima S, Yoshida S, Chen W, Fukushima H, Tanaka H, Sato H, Hirakawa A, Masuda H, Fujii Y. PMID: 42502892 [PubMed - indexed for MEDLINE]
	Identifying and characterizing the germinal genetic landscape of men with prostate cancer: A real-life, retrospective, multicenter study. Genet Med Open Svirsky R, Sonnenfeld B, Kedar I, Linial M, Azulay N, Sharabi-Nov A, Shalev H, Goldberg Y. PMID: 42502690 [PubMed]
	Evaluating Locally Deployed Large Language Models for Ga-68 PSMA PET/CT Report Mining in Prostate Cancer. Nucl Med Mol Imaging Chaudhary J, Sharma PD, Kumar S, Takalkar N, Kumar R, Haresh KP, Das CJ, Sahoo RK, Kaushal S, Kalaivani M, Khairwa H, Pandey AK. PMID: 42502653 [PubMed]
	Beyond EMT: Mesenchymal drift as an emerging driver of stromal-immune reprogramming in prostate cancer. iScience Zhang Z, Liu F, Liu S, Ning H, Sun Y, Wu F. PMID: 42502394 [PubMed]
	Preoperative prediction of positive surgical margins in prostate cancer using multimodal deep learning model: a multicenter study. Abdom Radiol (NY) Fu X, Bao J, Qiao X, Shen J, Zhang Y, Jin P, Ji Y, Zhang J, Su Y, Ji L, Li Z, Hu C, Lu J, Wang X, Shen H, Liu J. PMID: 42501097 [PubMed - as supplied by publisher]
	Impact of tumor immunotherapy on kidney injury and multi-organ outcomes: a mechanistic and clinical perspective. Front Immunol Jiang L, Wang J, Xiong S, Min S, Gong N. PMID: 42500665 [PubMed - indexed for MEDLINE]
	First-Line Treatment Strategies in IMDC Favourable-Risk Metastatic Clear Cell Renal Cell Carcinoma. Oncol Res Valdés A, González-Montero J, Rojas C, Burotto M. PMID: 42500582 [PubMed - indexed for MEDLINE]
	Immunohistochemical Expression of Novel Therapeutic Targets in Squamous Cell Carcinoma of the Bladder. Oncol Res Frey LJ, Lache N, Fischer ND, Rölz N, Frey L, Haack M, Duwe G, Porubsky S, Haferkamp A, Wagner DC, Brandt MP. PMID: 42500580 [PubMed - indexed for MEDLINE]
	Integrative genomic profiling identifies MLPH as a candidate gene in prostate cancer. Front Med (Lausanne) Wang R, Wang J, Zhao Z, Hu X. PMID: 42500538 [PubMed]
	Perioperative Systemic Treatment Patterns and Postoperative Mortality Among Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy in Japan: WAKKA-MIBC Study. Int J Urol Kikuchi E, Tokumaru J, Kawai D, Ide R, Komazaki H, Kitagawa H, Inokuchi J. PMID: 42499313 [PubMed - indexed for MEDLINE]
	Short-term clinical outcomes of cytoreductive radical prostatectomy combined with abiraterone-based androgen deprivation therapy in oligometastatic prostate cancer. Medicine (Baltimore) Li B, Qin Q, Liao J, Li L, Wang X, Hao P, Zhang A, Zhang G, Huang C. PMID: 42499100 [PubMed - indexed for MEDLINE]
	Identification of immune-related prognostic genes and construction of a risk model for Wilms tumor: A retrospective bioinformatics study. Medicine (Baltimore) Chen J, Yang G, Zhu Z, Liao J, Gu H. PMID: 42499033 [PubMed - indexed for MEDLINE]
	Systematic Review and Meta-analysis on Renal Tumor Biopsy: Accuracy, Safety, and Impact on Clinical Decision-making. Eur Urol Mjaess G, Nicolazzini M, Amparore D, Bex A, Campi R, Cei F, Noyes SL, Re C, Rosiello G, Stewart GD, Volpe A, Palumbo C, European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group. PMID: 42498608 [PubMed - as supplied by publisher]
	Ideal candidates for bladder preservation in muscle-invasive bladder cancer. Urol Oncol Oberoi JK, Ballas LK, Tyson M, Singh P. PMID: 42498593 [PubMed - as supplied by publisher]
	A spotlight on PTEN alterations in prostate cancer: a narrative review. Crit Rev Oncol Hematol Alaimo D, Di Costanzo F, Oltrecolli M, Oing C, Castro E, Rescigno P. PMID: 42497972 [PubMed - as supplied by publisher]
	Identification and validation of TP53/p53 status as a prognostic marker in penile squamous cell carcinoma: Evidence from a cohort study and meta-analysis. Urol Oncol Cai Z, Jin H, Guo Y, Chen D, Huang G, Jiang X, Liu J, Chen BN, Zhang X, Chen Z, Li Z. PMID: 42497775 [PubMed - as supplied by publisher]
	Not always a perfect match: discrepancies between PSMA PET/CT and MRI in prostate cancer diagnosis and staging. Abdom Radiol (NY) Lemos A, Woo S, Novaes A, Lucano M, Oliveira J, Torres C, Fukumori O, Gouvea G, Reis R, Vargas A, Muglia V. PMID: 42496916 [PubMed - as supplied by publisher]
	Does an emphasis on urinary continence compromise oncological outcomes after robot-assisted radical prostatectomy? World J Urol Matsumoto K, Fukumoto K, Yasumizu Y, Tanaka N, Takeda T, Asanuma H. PMID: 42496719 [PubMed - indexed for MEDLINE]
	Histotripsy for renal cell carcinoma: from animal studies to clinical application. Int J Hyperthermia Mutlu A, Falk KL, Kisting AL, Knavel Koepsel EM, Wagner MG, Hinshaw JL, Shapiro DD, Abel EJ, Swietlik JF, Laeseke PF, Ziemlewicz TJ, Lee FT, Golden ED. PMID: 42495873 [PubMed - indexed for MEDLINE]
	ACP3-targeted PET imaging agents based on small-molecule ligands for prostate cancer diagnostics and theranostics. Am J Nucl Med Mol Imaging Liang SH. PMID: 42495193 [PubMed]

Artikel 1 - 20 / 180299

Seite 1 von 9015

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung